StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen GAAP Diluted Earnings Per Share by Quarter

GAAP Diluted Earnings Per Share ($/sh) ($)

QuarterlyAnnual

Amgen GAAP Diluted Earnings Per Share: $4.37 in Q2 2026, up 64.9% from a year earlier.

Latest, Q2 2026
4.37
Period ended Jun 30, 2026
Change on a year earlier
+64.9%
2.65 in Q2 2025
History
34 quarters
Since Q3 2017
Sources
30
Documents cited below

Where the Q2 2026 figure comes from

“|| Diluted EPS | $ | 4.37 | $ | 6.29 | $ | 2.65 | $ | 6.02”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGAAP Diluted Earnings Per Share ($/sh) ($)Year on yearSource
Q2 2026Jun 30, 20264.37+64.9%Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20263.34+4.4%Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 20252.45+111.2%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 20255.93+13.6%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 20252.65+92.0%Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 20253.20–Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2024Dec 31, 20241.16-18.3%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 20245.22+62.1%Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20241.38-46.3%Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q4 2023Dec 31, 20231.42-52.7%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 20233.22-19.1%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 20232.57+4.9%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 20235.28+97.0%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20223-10.7%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 20223.98+20.2%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 20222.45+202.5%Form 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗

Cite this data

StockData. (2026). Amgen GAAP Diluted Earnings Per Share ($), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap-eps-diluted-8k

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.